English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/50352
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
DC FieldValueLanguage
dc.contributor.authorAlbajar, Marta-
dc.contributor.authorGómez-Casares, M. Teresa-
dc.contributor.authorMauleon, Itaso-
dc.contributor.authorVaqué, José P.-
dc.contributor.authorAcosta, Juan C.-
dc.contributor.authorDelgado, M. Dolores-
dc.contributor.authorLeón, Javier-
dc.date.accessioned2012-05-29T10:32:06Z-
dc.date.available2012-05-29T10:32:06Z-
dc.date.issued2011-
dc.identifierdoi: 10.1158/1541-7786.MCR-10-0356-
dc.identifierissn: 1541-7786-
dc.identifier.citationMolecular Cancer Research 9(5): 564-576 (2011)-
dc.identifier.urihttp://hdl.handle.net/10261/50352-
dc.descriptionEl pdf es la versión post-print.-- et al.-
dc.description.abstractUntreated chronic myeloid leukemia (CML) progresses from chronic phase to blastic crisis (BC). Increased genomic instability, deregulated proliferation, and loss of differentiation appear associated to BC, but the molecular alterations underlying the progression of CML are poorly characterized. MYC oncogene is frequently deregulated in human cancer, often associated with tumor progression. Genomic instability and induction of aberrant DNA replication are described as effects of MYC. In this report, we studied MYC activities in CML cell lines with conditional MYC expression with and without exposure to imatinib, the front-line drug in CML therapy. In cells with conditional MYC expression, MYC did not rescue the proliferation arrest mediated by imatinib but provoked aberrant DNA synthesis and accumulation of cells with 4C content. We studied MYC mRNA expression in 66 CML patients at different phases of the disease, and we found that MYC expression was higher in CML patients at diagnosis than control bone marrows or in patients responding to imatinib. Further, high MYC levels at diagnosis correlated with a poor response to imatinib. MYC expression did not directly correlate with BCR-ABL levels in patients treated with imatinib. Overall our study suggests that, as in other tumor models, MYC-induced aberrant DNA synthesis in CML cells is consistent with MYC overexpression in untreated CML patients and nonresponding patients and supports a role for MYC in CML progression, possibly through promotion of genomic instability. ©2011 AACR.-
dc.description.sponsorshipThis work was supported by a grant from the Ministerio de Ciencia e Innovacion of Spain (SAF08-01581) and by the RTICC (Red Temática de Investigación Cooperativa en Cancer, RD06/0020/0017) to J. León and a grant from Instituto de Salud Carlos III (FIS08/0829) to M.D. Delgado.-
dc.language.isoeng-
dc.publisherAmerican Association for Cancer Research-
dc.rightsopenAccess-
dc.titleMYC in chronic myeloid leukemia: Induction of aberrant DNA synthesis and association with poor response to imatinib-
dc.typeartículo-
dc.identifier.doi10.1158/1541-7786.MCR-10-0356-
dc.date.updated2012-05-29T10:32:06Z-
dc.description.versionPeer Reviewed-
Appears in Collections:(IBBTEC) Artículos
Files in This Item:
File Description SizeFormat 
MYC in chronic.pdf584,21 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.